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Traditionally, hyperbaric oxygen treatment (HBOT) is indicated in several clinical disorders include decompression
sickness, healing of problem wounds and arterial gas embolism. However, some investigators have used HBOT to
treat individuals with autism spectrum disorders (ASD). A number of individuals with ASD possess certain
physiological abnormalities that HBOT might ameliorate, including cerebral hypoperfusion, inflammation,
mitochondrial dysfunction and oxidative stress. Studies of children with ASD have found positive changes in
physiology and/or behavior from HBOT. For example, several studies have reported that HBOT improved cerebral
perfusion, decreased markers of inflammation and did not worsen oxidative stress markers in children with ASD.
Most studies of HBOT in children with ASD examined changes in behaviors and reported improvements in several
behavioral domains although many of these studies were not controlled. Although the two trials employing a
control group reported conflicting results, a recent systematic review noted several important distinctions between
these trials. In the reviewed studies, HBOT had minimal adverse effects and was well tolerated. Studies which used
a higher frequency of HBOT sessions (e.g., 10 sessions per week as opposed to 5 sessions per week) generally
reported more significant improvements. Many of the studies had limitations which may have contributed to
inconsistent findings across studies, including the use of many different standardized and non-standardized
instruments, making it difficult to directly compare the results of studies or to know if there are specific areas of
behavior in which HBOT is most effective. The variability in results between studies could also have been due to
certain subgroups of children with ASD responding differently to HBOT. Most of the reviewed studies relied on
changes in behavioral measurements, which may lag behind physiological changes. Additional studies enrolling
children with ASD who have certain physiological abnormalities (such as inflammation, cerebral hypoperfusion, and
mitochondrial dysfunction) and which measure changes in these physiological parameters would be helpful in
further defining the effects of HBOT in ASD.
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Hyperbaric oxygen treatment (HBOT) involves inhaling
up to 100% oxygen at a pressure greater than one at-
mosphere (atm) in a pressurized chamber [1]. HBOT is
indicated in several clinical disorders include decom-
pression sickness, healing of problem wounds, arterial
gas embolism and carbon monoxide poisoning [2].
Treatment with HBOT for these disorders uses higher
pressures (over 2.0 atm). Higher pressure HBOT has* Correspondence: rossignolmd@gmail.com
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reproduction in any medium, provided the orbeen shown to increase the oxygen content of plasma
[3] and body tissues [4] and may normalize oxygen levels
in ischemic tissues [5].
As compared to treatment with HBOT for many clas-
sical indications, HBOT used at lower pressures (e.g. 1.3
to 1.5 atm and oxygen at 24 to 100%) has started to be
investigated to treat certain neurological disorders, some
of which are considered to have few efficacious treat-
ments. For example, recent studies have investigated
lower pressure HBOT for traumatic brain injury (TBI) in
both animal models [6-10] and humans [11-23]. In a re-
cent prospective trial of 16 patients with TBI, HBOT at
1.5 atm/100% oxygen (40 hourly treatments over 30 days)ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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logical exam, IQ, memory, post-traumatic stress symp-
toms, depression, anxiety and quality of life. Patients
also displayed objective improvements in brain perfusion
measured by pre- and post-HBOT single photon emis-
sion computed tomography (SPECT) scans [17]. The
human studies of TBI also include a controlled retro-
spective review and a controlled prospective clinical trial
[15,18]. Larger multicenter trials are ongoing in attempt
to confirm these controlled clinical studies [24].
Other neurological disorders have been reported to
improve with lower pressure HBOT; one investigator
reported significant improvements in IQ for a 15 year
old child who had fetal alcohol syndrome using HBOT
at 1.5 atm/100% oxygen for 73 sessions [25]. Some
investigators have reported that HBOT possesses
neuroprotective effects [8,26,27]. Interestingly, oxygen
supplementation has recently been reported to enhance
cognition [17]. For example, in several double-blind
studies of healthy young adults, the use of supplemen-
tary oxygen, when compared with room air, significantly
enhanced memory [28], cognitive performance, word re-
call and reaction time for 24 hours [29], as well as atten-
tion and picture recognition [30].
Autism spectrum disorders (ASD) are a heterogeneous
group of neurodevelopmental disorders that are defined by
behavioral observations and are characterized by impair-
ments in communication and social interaction along with
restrictive and repetitive behaviors [31]. ASD includes aut-
istic disorder, Asperger syndrome, and pervasive develop-
mental disorder-not otherwise specified (PDD-NOS). An
estimated 1 out of 110 individuals in the United States is
currently affected with an ASD [32]. The etiology of ASD
is unclear at this time. Although several genetic syn-
dromes, such as Fragile X and Rett syndromes, have been
associated with ASD, empirical studies have estimated that
genetic syndromes only account for 6-15% of ASD cases
[33]. Therefore, the majority of ASD cases are not due to a
simple single gene or chromosomal disorder. Although
many of the cognitive and behavioral features of ASD are
thought to arise from dysfunction of the central nervous
system (CNS), evidence from many fields of medicine has
documented multiple non-CNS physiological abnormal-
ities associated with ASD [34-37], suggesting that, in some
individuals, ASD arises from systemic, rather than organ
specific, abnormalities. Specifically, in recent decades, re-
search and clinical studies in ASD have implicated physio-
logical and metabolic systems that transcend specific
organ dysfunction, such as cerebral hypoperfusion, im-
mune dysregulation, inflammation, oxidative stress, and
mitochondrial dysfunction [38,39]. In this context, ASD
may arise from, or at least involve, systemic physiological
abnormalities rather than being a purely CNS disorder, at
least in a subset of individuals with ASD [40].To date, ASD has few efficacious treatments. Applied
Behavioral Analysis (ABA) is a form of behavioral ther-
apy which has been reported to lead to improvements in
some children with ASD. ABA treats the behavioral
manifestations of ASD. Studies of ABA generally observe
children with ASD over a period of one to two years.
Lovaas first reported that ABA resulted in significant
gains in IQ and behavioral problems over a 2 year period
of time in some children with ASD [41]. Researchers
from the Wisconsin Early Autism Project observed simi-
lar behavioral and IQ improvements with ABA after
4 years of observations [42]. However, only modest gains
were detected using ABA compared to eclectic therapy
by researchers in Norway when children were observed
for only one year [43]. Therefore, behavioral therapies
typically require long time periods to cause behavioral
and cognitive changes in children with ASD.
Some treatments for ASD target physiological abnor-
malities that have been reported in some children. How-
ever, very few of these types of treatments have been
critically evaluated. Starting around 2005, some investi-
gators speculated that HBOT may be useful in improv-
ing behavioral and physiological abnormalities found in
some children with ASD [44-48]. This manuscript will
review the current evidence for HBOT as a treatment
for ASD. First, the effects of HBOT on physiological ab-
normalities in children with ASD will be reviewed. Sec-
ondly, the effects on autistic behaviors will be discussed.
Finally, potential adverse effects of HBOT in ASD and
limitations of studies will be reviewed.
The effects of HBOT on physiological abnormalities in
ASD
Cerebral hypoperfusion in ASD and the effects of HBOT
A number of studies have reported cerebral hypoperfusion
in individuals with ASD compared to controls as measured
by positron emission tomography (PET), SPECT or func-
tional magnetic resonance imaging (fMRI) [49-51]. This
hypoperfusion has been correlated with certain autistic
behaviors such as repetitive behaviors [52], desire for
sameness [53], impairments in processing facial expres-
sions and emotions [54], and decreased language develop-
ment [55]. Furthermore, lower cerebral perfusion has been
significantly correlated with increasing age in children with
ASD [55] and with more severe autistic behaviors [56].
It is possible that HBOT could improve cerebral perfusion
in ASD. Several studies have reported significant improve-
ments in cerebral perfusion with the use of HBOT at lower
pressures (i.e., 1.3 to 1.5 atm), as measured by pre- and post-
HBOT SPECT scans in several neurological conditions, in-
cluding TBI and chronic brain injury [16,17,19,22]. In
addition, cerebral perfusion has been shown to change in
children with ASD after treatment with HBOT. For example,
several case reports have demonstrated improvements in
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SPECT scans, with the use of HBOT at 1.3 atm/24% oxygen,
including one child with ASD who received 1 hour of HBOT
per day for 10 consecutive days [57] and two children with
ASD who received 40–80 treatments [58]. Behavioral
improvements were observed in these children as well.
Figure 1a-b demonstrates the pre- and post-HBOT SPECT
scans in one child from this latter case report [58].
Kinaci et al. reported on the cerebral perfusion effects of
HBOT at 1.5 atm/100% oxygen for 50 sessions at 60Figure 1 SPECT scan images in a 12 year old boy with autism (a) befo
(green) to minus 4 (blue) standard deviations indicate the magnitude of re
improvement in deeper cortical hypoperfusion patterns. Red arrows on sag
improvements after HBOT. Yellow arrows on the “underside” view show th
Pictures courtesy of J. Michael Uszler, MD. Credit: Permission for use of figu
Publishing Company, Palm Beach Gardens, FL.minutes per day in 108 children with ASD [59]. At baseline,
all 108 patients had normal MRI scans and decreased tem-
poral lobe perfusion as measured by SPECT scans, while
88% had decreased frontal lobe perfusion and 61% had
decreased perfusion to other brain areas. Post-treatment
HBOT SPECT scans demonstrated that 82.4% of the
patients had an improvement in temporal lobe perfusion,
85.3% improved in frontal lobe perfusion, and 75.8% had
improvements in perfusion to other brain areas. Behavioral
improvements were also observed in these children.re and (b) after 80 sessions of HBOT at 1.3 atm. Legend: minus 2
gional hypofunctioning (hypoperfusion). White arrows indicate
ittal slices show the midline cerebellum hypoperfusion and
e temporal lobe hypoperfusion with improvements after HBOT.
re from Hyperbaric Oxygen for Neurological Disorders granted by Best
Figure 2 6 year old boy with autism who received HBOT at
1.5 atm. Before HBOT, physical exam reveals distended
abdomen (a) with chronic diarrhea. After HBOT, patient has
improvements in distended abdomen (b) and bowel movements.
Figure use with parental permission. Credit: Permission for use of
figure from Hyperbaric Oxygen for Neurological Disorders granted
by Best Publishing Company, Palm Beach Gardens, FL.
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(SPECT imaging), evaluations by clinicians, and a larger
sample size than other studies.
Inflammation in ASD and the effects of HBOT
Recent studies support the notion that some individuals
with ASD manifest neuroinflammation, immune dysregula-
tion and/or gastrointestinal inflammation. A recent review
reported that 416 publications implicated inflammation or
immune abnormalities in ASD, including 65 publications of
neuroinflammation and 31 publications of gastrointestinal
inflammation [38]. A number of studies suggest that the
gastrointestinal inflammation reported in some children
with ASD has characteristics similar to inflammatory bowel
disease (IBD) [60-63]. Furthermore, several studies have
reported abnormal inflammatory markers in some children
with ASD. For example, elevations in TNF-alpha [64-67]
and neopterin (a marker of activation of the cellular im-
mune system) [68-70] have been reported in several studies
of children with ASD.
Treatment with HBOT has been shown to possess potent
anti-inflammatory properties in both animal [71-73] and
human studies [74-78]. HBOT has been reported to de-
crease the production of pro-inflammatory cytokines (in-
cluding TNF-alpha, interferon-gamma, IL-1 and IL-6) in
both animal [79,80] and human studies [78,81] as well as in-
crease counter-inflammatory IL-10 levels [82]. In one study,
HBOT also decreased neopterin levels [83]. Furthermore, a
recent systematic review reported improvements in studies
that used HBOT in IBD [84]. The effect of HBOT on redu-
cing inflammation may be mediated through a pressure-
related effect and not necessarily by the oxygen delivered.
For example, one human study reported a reduction in
interferon-gamma production by lymphocytes with HBOT
at 2.0 atm/10.5% oxygen but an increase in interferon-
gamma with 100% oxygen delivered at 1.0 atm [78].
Two prospective studies have examined the effects of
HBOT on biomarkers of inflammation in children with
ASD [85,86]. In the first study, 12 children received HBOT
at 1.3 atm/24% oxygen and 6 children received HBOT at
1.5 atm/100% oxygen. Biomarkers were measured before
and after 40 HBOT sessions [85]. C-reactive protein (a gen-
eral marker of inflammation) dropped in the overall study
population (p=0.021). Children who had the highest C-
reactive protein levels showed the largest decrease. Behav-
ioral improvements were also observed in these children.
In the second study, plasma cytokine levels, including
some associated with inflammation, were measured be-
fore and after 80 HBOT sessions delivered at 1.5 atm/
100% oxygen over a 20 week period in 10 children with
ASD [86]. Behavioral improvements were observed in
these children, but the study reported no significant
changes in cytokines during the study. However, the
authors noted that none of the children had abnormalcytokine levels at the beginning of the study, making it
less likely that a significant change could be observed.
Furthermore, since cerebrospinal fluid (CSF) cytokine
abnormalities have been reported in some children with
ASD [64,87,88], the authors noted that CSF cytokines
could have changed. However, CSF cytokines were not
measured in the study. Further studies of HBOT in chil-
dren with ASD who have abnormal cytokines and mar-
kers of inflammation are warranted to investigate these
findings in more depth.
In addition to these two studies, one of the authors
(DAR) has observed a decrease in urinary neopterin
levels after HBOT in some children. For example, one
child with ASD who was treated with HBOT at 1.5 atm/
100% oxygen for 40 treatments over 1 month had a drop
in urinary neopterin, measured immediately before start-
ing HBOT and immediately after stopping, from 768 to
391 μmol/mol creatinine, respectively. Another child
with ASD who had significant eczema and bowel inflam-
mation with abdominal distension had resolution of ec-
zema, chronic diarrhea and abdominal distension with
HBOT at 1.5 atm/100% oxygen for 40 treatments over
1 month [58]. See Figure 2a-b for pre- and post-HBOT
pictures of this child.
Mitochondrial dysfunction in ASD and the effects of HBOT
Some individuals with ASD manifest evidence of mito-
chondrial dysfunction [34,89]. A recent review article
reported that 145 publications implicated mitochondrial
dysfunction in ASD [38]. Although treatments for mito-
chondrial dysfunction remain relatively limited [34], inter-
est has recently increased in using HBOT as a potential
treatment. Both animal and human studies have examined
the effects of HBOT on mitochondrial function. Several
animal models have reported improvements in mitochon-
drial function with HBOT [90-96]. For example, in one
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increased the production of ATP in muscle tissue com-
pared to a control group [97]. A recent study of rat hippo-
campus reported that HBOT increased mitochondrial
biogenesis and autophagy through, in part, an increased
production of reactive oxygen species (ROS). Through this
process, new healthy mitochondrial were produced and
old dysfunctional mitochondrial were destroyed. This
study also found increased activation of mitochondrial
DNA transcription and replication with HBOT [98]. In a
recent controlled study of 69 patients with severe TBI,
HBOT at 1.5 atm/100% oxygen significantly increased
brain oxygen levels, increased cerebral blood flow, and
decreased CSF lactate levels (high CSF lactate is a marker
of mitochondrial dysfunction). In this study, HBOT also
improved brain metabolism and mitochondrial function
compared with both room air treatment and 100% oxygen
given at normobaric pressure [18]. Although one investiga-
tor has reported improvements using HBOT in children
with concomitant mitochondrial disease and ASD [99], no
clinical studies have been published to date examining the
effects of HBOT on mitochondrial function in individuals
with ASD; further study in this area is needed.
Oxidative stress in ASD and the effects of HBOT
Multiple studies have reported evidence of oxidative stress in
children with ASD [36,100-102]. A recent review article
reported that 115 publications implicated oxidative stress in
ASD [38]. Since some children with ASD have evidence of
elevated oxidative stress [38,100], some investigators have
expressed concern that HBOTcould increase oxidative stress
in this subset of children [85]. Theoretically, HBOT might
increase oxidative stress through the augmented production
of ROS from the high concentration of oxygen [103]. This
may occur because increased oxygen delivery to mitochon-
dria can increase ROS production. However, HBOT has
been shown to upregulate the production of antioxidant
enzymes such as superoxide dismutase [104,105], glutathi-
one peroxidase [106], catalase [107], paraoxonase [108] and
heme-oxygenase 1 [109,110]. This increase in antioxidant
enzyme levels has been termed “conditioning” and can pro-
tect against damage caused by ROS [44,111]. Interestingly,
increasing ROS may be a potential mechanism of action of
HBOT because ROS play an important role in cellular sig-
naling and in triggering certain metabolic pathways [112].
Furthermore, as previously discussed, a slight increase in
ROS produced by HBOT may be beneficial as these ROS ap-
pear to augment mitochondrial biogenesis [98].
Two studies have reported measurements of oxidative
stress markers before and after HBOT in children with ASD
[85,113]. In the first study, HBOT was administered daily at
1.3 atm to 48 children with ASD, and superoxide dismutase
(SOD), catalase and glutathione peroxidase levels were mea-
sured before starting HBOT and after 1 day and 32 days ofHBOT [113]. SOD was 4.5-fold and 4.7-fold higher at 1 and
32 days after starting HBOT, respectively. Mean catalase
increased by 1.9-fold after 1 day and after 32 days was 90%
of the initial level before beginning HBOT. Finally, mean
glutathione peroxidase increased by 1.4-fold after 1 day and
after 32 days was 1.2-fold higher than before beginning
HBOT. The effects of HBOT on these antioxidant enzymes
may be an example of conditioning as previously discussed.
In the second prospective study, 12 children with ASD
received HBOT at 1.3 atm/24% oxygen and 6 children
received HBOT at 1.5 atm/100% oxygen. Biomarkers
were measured before and after 40 HBOT sessions [85].
Behavioral improvements were observed in these chil-
dren and plasma oxidized glutathione levels did not sig-
nificantly change at 1.3 atm (p = 0.557) or 1.5 atm
(p = 0.583). Since oxidized glutathione is exported from
cells when intracellular levels exceed the redox capacity
[114], this finding suggests that intracellular oxidative
stress did not significantly worsen with HBOT at these
two commonly used lower HBOT pressures in ASD
[85].
The effects of HBOT on behavioral measurements in ASD
The majority of treatment studies using HBOT in chil-
dren with ASD have measured behavioral rather than
physiological parameters. These behavioral studies can
be divided into those with and without control children.
Studies lacking control children
Several case studies have reported behavioral improve-
ments in individuals with ASD from treatment with
HBOT. The first published report of the use of HBOT in
an individual with ASD was in 1994 [115]. In this report,
treatment with HBOT resulted in improvements in mood
and social interactions in a three year old child with ASD.
The number of treatments and other HBOT parameters
were not reported. In 2002, Heuser et al. reported a “strik-
ing improvement” in behavior, memory, social interaction,
verbalizations and cognitive functioning in a 4 year old
boy with ASD after HBOT treatment at 1.3 atm/24% oxy-
gen for 10 consecutive days [57]. Another investigator
observed significant objective improvements in coloring
skills (see Figure 3a-d) as well as speech and self-help skills
in a 17 year old child with ASD using HBOT at 1.5 atm/
100% oxygen for 20 sessions [116]. Burke noted improve-
ments in 2 children with ASD using HBOT at 1.3 atm/
28% oxygen, including improvements in communication,
aggressiveness and social interaction [117]. Another report
noted objective improvements in one child with ASD in
handwriting (Figure 4a-b) after 40 treatments with HBOT
at 1.3 atm/24% oxygen, as well as improvements in fine
motor skills, bowel function, language and communication
[58]. One investigator reported improvements in language,
social interaction and overall cognition in a 3 year old boy
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ments. This child also had chronic diarrhea and had the
first normal bowel movement in his life with HBOT treat-
ment [99]. In another report, 23 patients with ASD had
various improvements in social interaction, language and
repetitive behaviors with HBOT at 1.5 atm [47]. Finally,
one prospective study of 20 children with ASD reported
improvements in communication, social interaction andFigure 3 Coloring book pages from 17 year old girl with autism: (a) b
week of HBOT (5 sessions at one hour each), she is beginning to crea
(about 15 hours of HBOT), she uses correct colors for Winnie the Poo
after 5 weeks of HBOT (20 hours of HBOT), she begins to respect bor
color. After 6 months, her coloring abilities remained stable. Pictures court
granted by the Journal of American Physicians and Surgeons.stereotypical behaviors after 20 HBOT sessions at 1.5 atm/
100% oxygen [118].
The first published case-series to examine the effects of
HBOT in 6 children with ASD administered HBOT at
1.3 atm/28% oxygen (1 hour treatments for 40 treatments)
[119]. Improvements were reported on the Autism Treat-
ment Evaluation Checklist (ATEC), the Childhood Autism
Rating Scale (CARS) and the Social Responsiveness Scaleefore beginning HBOT at 1.5 atm/100% oxygen; (b) after one
te patches of color to fill in a space; (c) after 3 weeks of HBOT
h and Eyore, and the foliage except for the tree trunk; and (d)
ders and boundaries and even outlines the inner border with
esy of Carol L. Henricks, MD. Credit: Permission for use of drawings
Figure 4 Handwriting in a 6 year old boy (a) before and (b)
after 40 HBOT sessions at 1.3 atm. Pictures courtesy of James
Neubrander, MD. Credit: Permission for use of figure from Hyperbaric
Oxygen for Neurological Disorders granted by Best Publishing
Company, Palm Beach Gardens, FL.
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children under age 5 compared to those older.
A follow-up prospective study examined the effects of
HBOT in 18 children with ASD [85]. Twelve children
were treated at 1.3 atm/24% oxygen and 6 were treated at
1.5 atm/100% oxygen. Hyperbaric sessions were 45 min-
utes in duration for 40 total sessions. As previously noted,
markers of oxidative stress and inflammation were mea-
sured. Pre- and post-HBOT parent-rated SRS and ATEC
indicated significant improvements in each group, includ-
ing motivation, speech, and cognitive awareness (p< 0.05
for each). Strengths of this study included the prospective
nature and the use of objective measurements (oxidative
stress and inflammatory markers). One group of investiga-
tors criticized this study, stating that significant improve-
ments were only observed when both groups (1.3 atm and
1.5 atm) were combined [120]; however, the improvements
were indeed significant for each group individually [85].
One small, prospective case series of 3 children with
ASD using a multiple baseline design reported no signifi-
cant improvements (compared to baseline) after 27–40
HBOT treatments at 1.3 atm/88% oxygen. The treatments
were 1 hour in duration, 5 days per week. However, one
child had an increase in spontaneous communication and
another child had a decrease in problem behaviors with
HBOT and an immediate increase in problem behaviors
when HBOT was stopped [121]. These improvements
were felt by the authors to be unrelated to HBOT but
could not necessarily be explained by other factors.
Strengths of this study included the prospective nature,
the multiple baseline design (including a baseline prior to
initiating HBOT), as well as evaluations by therapists and
videotaping.
Another prospective study from Thailand reported the
effects of HBOT at 1.3 atm/100% oxygen for 10 sessions
(one session per week) in 7 children with ASD [122].Significant improvements (p< 0.001 for each) were
observed in social interaction, fine motor and eye-hand
coordination, language, gross motor skills and self-help
scores. Strengths of this study included the prospective
nature and the objective measurements of self-help and
motor skills by therapists.
A large, retrospective study from Turkey using HBOT
at 1.5 atm/100% oxygen for 50 sessions at 60 minutes
per day reported pre- and post-HBOT ATEC scores [59].
As previously noted, improvements in cerebral perfusion
were observed on pre- and post-HBOT SPECT scans. As
rated by clinicians/therapists for 54 children with ASD,
improvements were observed in speech/language/com-
munication in 79%, sociability in 85.5%, sensory/cogni-
tive awareness in 87%, and health/physical/behavior in
75.2%. Strengths of this study included objective mea-
surements (SPECT imaging), evaluations by clinicians,
and a larger sample size than other studies.
One prospective study using a multiple baseline design
examined the effects of HBOT at 1.3 atm/24% oxygen
for 40 treatments in 16 children with ASD treated over
an average of 56 days [123]. The mean frequency of
treatments was 4.78 sessions per week with a range of
2.46 to 7.0 sessions. No consistent positive or negative
effects were observed. The authors noted that the study
used an observational technique which may not have
been sufficient to measure changes in certain areas, such
as attention and memory, and that the number of treat-
ments per week was about half as other studies which
reported improvements using similar HBOT parameters
in children with ASD. Strengths of this study included
the multiple baseline design (including a baseline prior
to initiating HBOT), as well as evaluations by therapists
and videotaping.
Finally, a more recent prospective study in 10 children
with ASD measured the effects of HBOT at 1.5 atm/100%
oxygen for 1 hour per day, 5 days per week for 80 treat-
ments (completed over 20 weeks, with a 4 week break be-
tween the 40th and 41st treatment) on several behavioral
scales as rated by parents and clinicians [86]. As previously
noted, cytokine markers were measured before and after
HBOT. Significant improvements were observed as mea-
sured by parent-rated ABC in irritability, lethargy, hyper-
activity and overall scores (p = 0.02 or less for each). On
the parent-rated PDD Behavior Inventory (PDD-BI), sig-
nificant improvements were observed in sensory problems,
specific fears, and aggressiveness (p= 0.006 or less for
each). Overall, parents reported improvements in eye con-
tact, imitation, language, tantrums, gastrointestinal pro-
blems and eczema. A significant improvement of 2 points
(corresponding to “much improved”) was observed on the
clinician-rated CGI-I scale in all 10 children. Strengths of
this study included the prospective nature, evaluations by
clinicians, and objective measurements (cytokine levels).
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In a recent systematic review published in Medical Gas
Research, Ghanizadeh reviewed two randomized, double-
blind, controlled trials using HBOT in children with aut-
ism [124]. The first study investigated the effects of HBOT
at 1.3 atm/24% oxygen for 40 treatments, utilizing 2 treat-
ments per day, 5 days per week, over 4 weeks in 33 chil-
dren with autistic disorder compared to 29 control
children with autistic disorder who received slightly pres-
surized room air (1.03 atm and 21% oxygen) [125]. Com-
pared to the control group, significant improvements were
observed in the treated children on the clinician-rated
CGI scale and the parent-rated CGI and ATEC scales in
outcomes including overall functioning, receptive lan-
guage, social interaction, eye contact and sensory/cognitive
awareness. Of the children completing more than 1 HBOT
session, one child dropped out of the study after nine
treatment sessions because asthma symptoms worsened,
but this was not felt to be related to the treatment.
Ghanizadeh noted that six other children dropped out of
the study (four before the study began and two before fin-
ishing one full treatment). In this study, six medical cen-
ters participated and the findings did not significantly
differ across centers. Strengths of this study included eva-
luations by blinded clinicians and parents (only the HBOT
technician was aware of group assignment), an assessment
of blinding (which was adequate), an intention-to-treat
analysis (children finishing more than 1 HBOT session
were included in the analysis), the prospective nature, the
use of a control group, and the use of 6 centers (which
may have minimized potential biases associated with a sin-
gle site study).
Several criticisms of this study [125] arose in the com-
ments sections of BMC Pediatrics and by other authors
[120,123]. One criticism was the claim that the effect of
treatment was determined by an intragroup analysis of
the treatment group alone, and not by an intergroup
analysis of the treatment compared to the control group;
however, the analysis was indeed an intergroup analysis
where the effects of treatment were compared between
the two groups. The authors noted that a typographical
error in the manuscript may have contributed to some
confusion as ± SEM (standard error of the mean) was
used when all of the reported values were actually ± SD
(standard deviation). Another criticism was that the ef-
fect size of the treatment was probably small; however,
the effect sizes were calculated as moderate to large
(0.55 for the ATEC sensory/cognitive awareness sub-
scale; 1.0 for physician-rated CGI score for overall func-
tioning; and 0.62 for parent-rated CGI score for overall
functioning [126]).
In the second controlled study, 18 children with autism
were treated with HBOTat 1.3 atm/24% oxygen for 80 ses-
sions (completed within 15 weeks) and compared to 16children treated with placebo (free air-flow through a
chamber at ambient pressure). Both groups received inten-
sive ABA therapy and no significant changes were
reported using several different behavioral scales [120].
Ghanizadeh [124] noted that twelve participants (26% of
the children entering the study) withdrew from the study.
It was not noted if these participants were in the treatment
group or the control group or when they dropped out of
the study; the scores from these 12 children were not
included in the final analyses. Ghanizadeh [124] also
observed that the number of patients in each group
was small and that both groups showed some improve-
ments during the study. Furthermore, it was noted by
Ghanizadeh [124] that since both groups received inten-
sive ABA therapy during the trial, one explanation for the
lack of efficacy observed is that HBOT did not add signifi-
cant therapeutic effects to intensive ABA. Strengths of this
study included the prospective nature, the use of a control
group and evaluation by blinded assessors.
Ghanizadeh [124] reported several important distinc-
tions between these two controlled trials [120,125] which
might help account for the different outcomes, including
the number of participants, potential differences in diagno-
ses, different age ranges of the study participants, different
outcome assessors, possible differences in demographics
and autism severity, multicenter [125] vs. single center trial
[120], assessment of blinding in one study [125] but not in
the second [120], and the intensity of treatments with one
study providing a mean of 10 hours of hyperbaric treat-
ments per week [125] and the other study providing, on
average, about 5 hours per week [120]. Ghanizadeh also
noted that one [120] of the studies had a relatively high
dropout rate which may have affected the results of the
study. Although the other controlled study had 7 children
drop out of the study, 4 dropped before starting the study
and two before finishing one treatment session [125].
Moreover, Ghanizadeh noted that for one of the studies
[120], there was no assessment of blinding efficacy as
described in other HBOT studies [127,128].
Adverse effects of HBOT in ASD
Most studies did not report any significant adverse
events using HBOT in individuals with ASD. Some stud-
ies specifically noted there were no adverse events
[85,119]. One study reported no adverse effects except
for transient tinnitus in one child which resolved within
one week [122]. Another study reported several non-
serious adverse events, including ear discomfort (4 chil-
dren), ear infections (2 children) and for 1 child each:
hyperactivity, increased vocal sensitivity, increased sen-
sory needs, insomnia, fatigue, dehydration, irritability,
mouthing of objects, and a seizure [86]. One of the con-
trolled studies reported that one child in the treatment
group developed both urinary frequency (urinalysis was
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thought was yeast-related. Another child in the treat-
ment group had worsening of asthma symptoms after
nine treatment sessions and was removed from the
study; a third child had anxiety and dropped out of the
study before finishing one full treatment. In the control
group, one child developed abdominal distension and
diarrhea during the study and another child had worsen-
ing of eczema [125]. The other controlled study reported
no adverse events in the treatment group but reported
that one of the children in the control group developed
hyponatremia and the acute onset of seizures and was
removed from the study [120]. In a recent systematic re-
view, Ghanizadeh highlighted that the use of HBOT in
children with ASD was associated with minimal adverse
events.
Limitations of the reviewed studies
Many of the reviewed studies suffered from limitations, in-
cluding the lack of control children, an open-label design,
a small number of participants, a retrospective design and
the use of parent-rated scales. Indeed, there were only two
controlled studies that did not suffer from these types of
limitations. These limitations may have contributed to in-
consistent findings across studies. In addition, some stud-
ies used measurements or observational techniques which
may not have been sufficient to measure changes in cer-
tain areas, such as attention and memory [123]. The
reviewed studies also utilized many different standardized
and non-standardized instruments, making it difficult to
directly compare the results of studies or to know if there
are specific areas of behavior in which HBOT is most ef-
fective. None of the studies reported measurements of the
long-term effects of HBOT beyond the study period, so it
is not known if any of the reported improvements were
long lasting.
Most of the reviewed studies relied on changes in behav-
ioral measurements, which may lag behind physiological
changes. Based on previous studies of ABA therapy in chil-
dren with ASD, it is not likely that substantial changes in
behavior will be detectable over short observation periods,
i.e., less than one year. In fact, studies on ABA therapy re-
port substantial changes over periods from 1 to 4 years
[41-43]. Given the complex requirements of brain develop-
ment, it is likely that the observed physiological and neuroi-
maging changes observed in children with ASD using
HBOT precede developmental and intellectual improve-
ments. In fact, the studies which examined physiological
changes with HBOT, especially changes in cerebral perfu-
sion, reported substantial changes which were often
observed over short periods of time. Although many of the
reviewed studies reported behavioral improvements in
some children with ASD, none of the studies lasted more
than several months. This time period is probably ofinsufficient length to quantify the impact of HBOT on de-
velopment. Additional studies examining the long term ef-
fect of HBOT in individuals with ASD are warranted.
Most studies reported improvements with HBOT in
physiological abnormalities and/or behavioral outcomes
of children with ASD; however, two studies from the
same group of researchers did not find any notable
improvements [120,123], and a third small study
reported minimal improvements [121]. The variability in
results between studies could have been due to certain
subgroups of children with ASD responding differently
to HBOT [123]. For example, it is possible that children
with abnormal cytokines, higher inflammatory markers,
cerebral hypoperfusion or mitochondrial dysfunction
may be more likely to demonstrate improvements. How-
ever, many of the behavioral studies did not measure
changes in biochemical variables (such as markers of in-
flammation or oxidative stress). One behavioral study
measured changes in cytokine levels, but all of the chil-
dren treated with HBOT had normal cytokine levels,
making it unlikely that a significant change in cytokines
would be observed [86]. Additional studies enrolling
children with ASD who have certain physiological ab-
normalities (such as inflammation or cerebral hypoper-
fusion) and which measure changes in these
physiological parameters would be helpful in investigat-
ing this further.
Studies which used a higher frequency of HBOT ses-
sions (e.g., 10 sessions per week as opposed to 5 sessions
per week) generally reported more significant improve-
ments. This appears to be consistent with studies in
other neurological conditions such as traumatic brain in-
jury [17] where studies using a higher mean number of
HBOT sessions per month (e.g., 40 treatments within a
one month period) generally reported more significant
effects. Additional studies are needed to look at various
HBOT parameters (pressure and oxygen levels) in chil-
dren with ASD to help determine optimal treatment
parameters.
Conclusions
HBOT at the pressures commonly used in children with
ASD (up to 1.5 atm/100% oxygen) has been reported to
improve cerebral perfusion, decrease markers of inflam-
mation and not worsen oxidative stress markers. Most
studies of HBOT in children with ASD reported
improvements in several behavioral domains although
many of these studies were not controlled. Although the
two trials employing a control group reported conflicting
results, a recent systematic review noted several import-
ant distinctions between these trials. Collectively, the
reviewed studies indicate that the use of HBOT in chil-
dren with ASD is associated with minimal adverse
events and is well tolerated. We conclude that HBOT is
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with ASD but that further studies are warranted. Future
studies would be wise to use standardized behavioral
measurement tools and physiological biomarkers in a
controlled study design. Targeting ASD subgroups that
possess specific physiological abnormalities with HBOT
may be a potentially fruitful method for determining
which ASD individuals would benefit from treatment
with HBOT.
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